Lucy Scientific Discovery (Lucy Scientific Discovery) Cash-to-Debt : 0.10 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Lucy Scientific Discovery Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lucy Scientific Discovery's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.10.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Lucy Scientific Discovery couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Lucy Scientific Discovery's Cash-to-Debt or its related term are showing as below:

LSDI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.1 Max: 1.95
Current: 0.1

During the past 3 years, Lucy Scientific Discovery's highest Cash to Debt Ratio was 1.95. The lowest was 0.00. And the median was 0.10.

LSDI's Cash-to-Debt is ranked worse than
84.2% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs LSDI: 0.10

Lucy Scientific Discovery Cash-to-Debt Historical Data

The historical data trend for Lucy Scientific Discovery's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lucy Scientific Discovery Cash-to-Debt Chart

Lucy Scientific Discovery Annual Data

Trend

Jun21

Jun22

Jun23

Cash-to-Debt

0.11

0.01

0.94

Lucy Scientific Discovery Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial						-	1.95	0.94	0.14	0.10

Competitive Comparison of Lucy Scientific Discovery's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Lucy Scientific Discovery's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lucy Scientific Discovery's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lucy Scientific Discovery's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lucy Scientific Discovery's Cash-to-Debt falls into.

Lucy Scientific Discovery Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lucy Scientific Discovery's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.674	/	(0.399	+	1.39)
	=	0.94

Lucy Scientific Discovery's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.211	/	(1.494	+	0.719)
	=	0.10

Lucy Scientific Discovery (NAS:LSDI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Lucy Scientific Discovery Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lucy Scientific Discovery's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lucy Scientific Discovery (Lucy Scientific Discovery) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lucy Scientific Discovery Inc (NAS:LSDI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6

Website

https://www.lucyscientific.com

Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.

Executives

Richard D Nanula	director, officer: Executive Chairman	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Charles B Nemeroff	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Paul Abramowitz	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brian Zasitko	officer: Chief Financial Officer	C/O LUCY SCIENTIFIC DISCOVERY, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Scott M. Reeves	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Christopher Mcelvany	director, officer: President and CEO	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Livio Susin	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brittany Kaiser	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Assad J Kazeminy	officer: Chief Scientific Officer	C/O LUCY SCIENTIFIC, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6